Challenges for Pharmacy in 2024

Last fall I joined Inmar Intelligence because of the great opportunity to work with an organization that is a healthcare, technology and media company uniquely positioned to help stakeholders successfully navigate the healthcare ecosystem. With the NACDS Annual Meeting drawing near, I’m compelled to share the key market forces that are informing Inmar’s strategy going forward. Our priorities will continue to evolve and I am excited to gain more insights from our customers and partners during NACDS Annual.

• Read more about Challenges for Pharmacy in 2024

A call for disruption and innovation in retail Rx

In preparing for the National Association of Chain Drug Stores Annual Meeting this year, I find myself thinking about the myriad opportunities reshaping retail pharmacy, including overcoming declining margins, winning expansion of pharmacist provider status, and leaning into consumer needs and value-based care. As I do so, I keep coming back to the guiding principle that we have been entrusted by our investors to create value by delivering patient safety, access and affordability in health care.

• Read more about A call for disruption and innovation in retail Rx

Inmar Intelligence Hosts 8th Medication Disposal Drive-Thru Event on April 27th

Safely dispose of unused or expired medications at Bolton Elementary School in Winston-Salem.

• Read more about Inmar Intelligence Hosts 8th Medication Disposal Drive-Thru Event on April 27th

Understanding DSCSA: Insights for All Dispensers

The article discusses how the DSCSA impacts medication dispensers, emphasizing compliance to protect patient safety and maintain supply chain integrity. It covers pharmaceutical crime, counterfeit drug risks, key DSCSA measures like product serialization, and stresses technology's role in ensuring authenticity. Compliance with regulations is crucial for a secure healthcare environment.

• Read more about Understanding DSCSA: Insights for All Dispensers

DIR reform in 2024: One step forward, two steps back

The article delves into the advancements and obstacles facing Direct and Indirect Remuneration (DIR) reform in 2024 within the pharmacy sector. It outlines the move from retroactive to upfront DIR fees, the financial pressures on pharmacies, and initiatives to broaden the scope of pharmacy services. Despite certain improvements like clawback elimination, the transition has introduced cash flow difficulties and decreased transparency. The article underscores the significance of comprehending and managing these reforms to bolster pharmacy viability and promote value-based care endeavors.

• Read more about DIR reform in 2024: One step forward, two steps back

Manufacturer CMOs Reevaluate Retail Media Network Investments

Inmar Intelligence Research Reveals Future Outlook of the State of Retail Media Networks

• Read more about Manufacturer CMOs Reevaluate Retail Media Network Investments

Successful Returns Management Starts With An Effective Returns Policy

Establishing a clear and consistent returns policy is an absolute requirement for any drug- or device-maker committed to successfully mitigating the financial liability attached to product flowing back through the supply chain.

• Read more about Successful Returns Management Starts With An Effective Returns Policy

US Department of Health and Human Services Selects Inmar Intelligence for a 5-year Contract to Deliver Pharmaceutical Supply Chain Solutions

Inmar Intelligence, a leading provider of data-driven healthcare technology solutions, today announced it has secured a contract with the US Department of Health and Human Services (HHS) to provide pharmaceutical supply chain solutions across the country.

• Read more about US Department of Health and Human Services Selects Inmar Intelligence for a 5-year Contract to Deliver Pharmaceutical Supply Chain Solutions

The Push for Healthcare Price Transparency: Will Pharmacies See a Benefit?

By Jason Murry, Senior Director, Healthcare Sales: Recent passage of the Lower Costs, More Transparency (LCMT) Act in a bipartisan vote by the U.S. House of Representatives is being heralded by the bill’s sponsors as “landmark legislation,” but is it really? The bill -- which is a long way from becoming law -- is focused on the very politically popular issue of lowering prescription drug prices for consumers. But where is the benefit for pharmacies?  

• Read more about The Push for Healthcare Price Transparency: Will Pharmacies See a Benefit?